Purchase this article with an account.
Katherine E. Uyhazi, Puya Aravand, Brent A. Bell, Zhangyong Wei, Lanfranco Leo, Leona Serrano, Denise J. Pearson, Ivan Shpylchak, Jennifer Pham, Vidyullatha Vasireddy, Jean Bennett, Tomas S Aleman; Treatment Potential for LCA5-associated Leber Congenital Amaurosis. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4500.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the therapeutic window for gene replacement in inherited retinal degenerations caused by mutations in the gene encoding Lebercilin (LCA5).
Five patients (ages 6-31) with Leber congenital amaurosis (LCA) and biallelic LCA5 mutations underwent a complete ophthalmic exam including spectral domain optical coherence tomography (SD-OCT), full-field stimulus testing (FST) and pupillometry. In the Lca5gt/gt mouse model of the disease, the time course of photoreceptor degeneration and the efficacy of subretinal gene replacement therapy with AAV8-hLCA5 administered in early (P5), mid (P15), and late (P30) stage disease were assessed using SD-OCT, histology, electroretinography (ERG), and pupillometry. Comparisons were made with the human disease.
Patients with LCA5 mutations have a maculopathy with detectable outer nuclear layer (ONL) in the pericentral retina and ~4 log units of sensitivity loss. The Lca5gt/gt mouse has a similarly severe and rapid photoreceptor degeneration. The ONL became progressively thinner and was undetectable by P60. Rod- and cone-mediated ERGs were severely reduced in amplitudes at P30 and became non-detectable by P60. Subretinal AAV8-hLCA5 administered to Lca5gt/gt mice at P5 and P15, but not at P30, resulted in structural and functional rescue.
LCA5-LCA is a particularly severe form of LCA that is recapitulated in the Lca5gt/gt mouse. Gene replacement results in structural and functional rescue in the Lca5gt/gt mouse if delivered before P30. Retained photoreceptors were visible within the central retina in all LCA5-LCA patients, in most at a level equivalent to that observed in rescued Lca5gt/gt mice, suggesting a window of opportunity for the treatment of LCA5-LCA patients.
This is a 2020 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only